Tier 3 — preclinical

Betaine Ameliorates Acute Sever Ulcerative Colitis by Inhibiting Oxidative Stress Induced Inflammatory Pyroptosis

Ling Chen, Dandan Liu, Mingli Mao, Wenjia Liu, Yajuan Wang, Yue Liang, Wenyu Cao, Xiaolin Zhong
Molecular nutrition & food research 2022 66(22):e2200341

Bibliography

PubMed
PMID 36069237
DOI
10.1002/mnfr.202200341
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignExperimental animal and/or laboratory research
ModelExperimental DSS-induced animal colitis model
SampleExperiment-specific biological replicates and model groups; see original methods
InterventionBetaine in chemically induced intestinal inflammation
DurationAcute experimental protocol
EndpointsColitis; Barrier integrity; Pyroptosis

What the study showed, in plain terms

Published in 2022, this source examined preclinical aging, brain and metabolic mechanisms. Design: Experimental animal and/or laboratory research. Sample/model: Experiment-specific biological replicates and model groups; see original methods. The exposure or intervention was Betaine in chemically induced intestinal inflammation. Follow-up or treatment period: Acute experimental protocol.

Betaine reduced selected disease-activity, barrier-injury and inflammatory-pyroptosis measures.

Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Betaine reduced selected disease-activity, barrier-injury and inflammatory-pyroptosis measures.
  • The recorded outcome domains were Colitis; Barrier integrity; Pyroptosis.
  • The result applies to the tested exposure: Betaine in chemically induced intestinal inflammation; Acute experimental protocol.

What this study can and cannot tell us

  • Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Systematic profiling reveals betaine as an exercise mimetic for geroprotection
Lingling Geng et al. · Cell · 2025
Tier 4
Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations
Emilia Zawieja et al. · Ageing research reviews · 2025
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology